Inflammasome targeting with an NLRP3 agonist therapy is feasible but ineffective in murine hepatocellular carcinoma models with liver damage
Z. Pu, Z. Liu, J. Chen, K. Inoue, Z. Ruan, L. Zhu, H. Kikuchi, A. Matsui, P. Huang, D. G. Duda
This study tests an NLRP3 agonist added to PD-1/VEGFR inhibitors in murine HCC models with liver damage, finding it feasible but ineffective in improving tumor outcomes.
bioRxiv · Jun 23, 2022 · PreprintImmunology